Read more about China s antitrust regulator bulking up as crackdown on behemoths widens on Business Standard. China s competition watchdog is adding staff and other resources as it ramps up efforts to crack down on anti-competitive behaviour
World Bank President David Malpass has said that with the Serum Institute, India is blessed to have a major manufacturer of global vaccines and he is encouraged by the country s ramping up of its domestic vaccination programme. Malpass made the comments on Monday during a media roundtable ahead of the spring meeting of the International Monetary Fund and World Bank. I ve had substantial contact with the Serum Institute. India is blessed with having a major manufacturer of global vaccines in India, he said. Responding to a question, Malpass said that he has encouraged more transparency in terms of what the national requirements are for local production, and that extends to countries around the world.
Lupin Ltd is quoting at Rs 1036.75, up 0.76% on the day as on 12:49 IST on the NSE. The stock is up 48.1% in last one year as compared to a 66.74% spurt in NIFTY and a 53.33% spurt in the Nifty Pharma.
Lupin Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 1036.75, up 0.76% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.15% on the day, quoting at 14659.7. The Sensex is at 49158.46, down 0%. Lupin Ltd has dropped around 1.3% in last one month.
Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has dropped around 1.78% in last one month and is currently quoting at 12331.5, up 1.03% on the day. The volume in the stock stood at 8.81 lakh shares today, compared to the daily average of 16.58 lakh shares in last one month.
Nepal will start its second phase of the COVID-19 inoculation drive from April 7 using a China-donated vaccine to fight against the deadly infection, according to the health ministry. The first phase of the vaccination drive began in January with the one million doses of Oxford-AstraZeneca vaccine provided by India under grant assistance in sync with its Neighbourhood First policy. The second phase will begin from Wednesday, April 7. The 800,000 doses of the China manufactured vaccine - Vero Cell- against COVID-19 infection will be administered to the frontline workers as well as those involved in trans-Himalayan trade activities in the mountainous region, Dr Jageshwor Gautam, the spokesperson for the Ministry of Health and Population, said.
A plant in the US which ruined 15 million potential doses of Johnson and Johnson s Covid-19 vaccine has been asked to stop producing doses for AstraZeneca, the media reported. The facility at Baltimore, Emergent Biosolutions, was earlier picked as a manufacturing partner for both AstraZeneca and Johnson and Johnson. In a statement on Saturday, Johnson and Johnson said it was assuming full responsibility regarding the manufacturing of drug substance for its Covid-19 vaccine at the Emergent BioSolutions. The development, first reported by The New York Times, could be a setback for AstraZeneca which is yet to receive approval for its Covid-19 vaccines in the US.